AbbVie increased its quarterly dividend by 5.5% to $1.73 per share even as its flagship drug Humira faces steep revenue declines due to patent expirations. Despite Humira's sales dropping 36.1% in Q2 2026 and nearly 50% in 2025, AbbVie's strong free cash flow and growing sales from newer drugs like Skyrizi and Rinvoq support the dividend growth. The company faces challenges with high leverage and upcoming patent expirations on newer drugs but remains confident in its pipeline and long-term dividend sustainability. Investors see AbbVie as fairly valued given its steady dividend and growth prospects amid the patent transition.
The FDA has approved a new subcutaneous induction regimen for SKYRIZI (risankizumab-rzaa) to treat adults with moderately to severely active Crohn's disease. This allows patients to start treatment at home using an on-body injector (OBI) device, impr...
Johnson & Johnson reported strong pharmaceutical growth with Innovative Medicine up 7.9%, driving optimism for its stock with a 12-month price target of $288.66, an 11.48% upside. However, its MedTech segment showed weak international sales growth an...
AbbVie announced positive Phase 3 INTREPID study results for lutikizumab, a dual IL-1α/1β antagonist, in treating moderate to severe hidradenitis suppurativa (HS). The study met its primary endpoint with 31.4% of patients achieving HiSCR75 at Week 16...
Retirees are increasingly turning to high-yield dividend stocks from diverse industries to supplement income beyond Social Security's fixed cost-of-living adjustments. Stocks like Verizon, Altria, AbbVie, Realty Income, and Enbridge offer yields from...
AbbVie has partnered with McLaren Racing as an Official Pharmaceutical Partner, launching the Race to Innovate campaign at the 2026 U.S. Grand Prix. For every 10 Constructors' Championship points McLaren earns, AbbVie will donate $10,000 to global ch...
